Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Wed, 03.07.2024
CureVac
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization
Prioritization of high-value opportunities in oncology a [ … ]
Wed, 03.07.2024
CureVac
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales miles [ … ]
Wed, 24.04.2024
CureVac
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making
Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas
TÜBINGEN, [ … ]
Thu, 18.04.2024
CureVac
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
TÜBINGEN, Germany/BOSTON, USA – April 18, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financ [ … ]
Tue, 16.04.2024
CureVac
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise
Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematologic [ … ]
Fri, 05.01.2024
CureVac
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile
M [ … ]
Tue, 19.12.2023
CureVac
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation
with BioNTech SE
Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE
Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering stron [ … ]
Tue, 14.11.2023
CureVac
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024
First participant dosed in seasonal flu Phase 2 study with potentially differentiated mul [ … ]
Wed, 01.11.2023
CureVac
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs
in Collaboration with GSK
COVID-19 Phase 2 clinical trial fully enrolled
Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine
First participant dosed in seasonal flu Phase 2 part of combined Phase [ … ]
Thu, 28.09.2023
CureVac
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech
Ruling on infringement to be provided latest once the validity of the intellectual property rights in suit has b [ … ]